A Multicentre, Open-label Trial Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

Trial Profile

A Multicentre, Open-label Trial Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Pharmacokinetics
  • Acronyms guardian ™9
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 25 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 29 May 2017 Planned End Date changed from 7 Jul 2017 to 6 Jul 2017.
    • 29 May 2017 Planned primary completion date changed from 5 May 2017 to 31 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top